Prenatal drug exposure: Infant and toddler outcomes

Journal of Addictive Diseases

Volumn 29, Issue 2, 2010, Pages 245-258

  Bandstra, Emmalee S ^a   Morrow, Connie E ^a   Mansoor, Elana ^a   Accornero, Veronica H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Cocaine; Heroin; Infant; Methadone; Pregnancy

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; MORPHINE; OPIATE; PHENOBARBITAL;

ADOLESCENCE; ALCOHOL CONSUMPTION; ANTHROPOMETRY; BEHAVIOR DISORDER; BEHAVIOR TERATOLOGY; BRAZELTON NEONATAL BEHAVIORAL ASSESSMENT SCALE; CHILD BEHAVIOR; CHILD GROWTH; CHILD HEALTH CARE; CHILD PARENT RELATION; COGNITION; COGNITIVE DEVELOPMENT; DRUG MEGADOSE; DRUG USE; EPIDEMIC; FETAL ALCOHOL SYNDROME; HEARING; HUMAN; LANGUAGE DEVELOPMENT; LOW DRUG DOSE; MATERNAL BEHAVIOR; MATERNAL WELFARE; MOTOR DEVELOPMENT; OPIATE ADDICTION; PASSIVE SMOKING; POSTNATAL GROWTH; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; REVIEW; SEIZURE; SMOKING; SUBSTANCE ABUSE; TERATOGENICITY; TODDLER; UNITED STATES; VISION; WITHDRAWAL SYNDROME;

BUPRENORPHINE; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COCAINE; COCAINE-RELATED DISORDERS; FEMALE; HEROIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHADONE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SUBSTANCE-RELATED DISORDERS;

EID: 77951443586     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550881003684871     Document Type: Review

References (92)

1. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: national findings. NSDUH Series H-34. Rockville, MD: Office of Applied Studies, 2008.
2. Bandstra ES, Accornero VH. Infants of substanceabusing mothers. In: Martin RJ, Fanaroff AA, Walsh MC (eds). Fanaroff and Martin's neonatal-perinatal medicine: diseases of the fetus and newborn. Philadelphia, PA:Mosby Elsevier Press; 2006:733-757
3. Abel EL, Sokol RJ. Fetal Alcohol Syndrome is now leading cause of mental-retardation. Lancet 1986; 2:1222.
4. Sulik K, Johnston M, Webb M. Fetal alcohol syndrome: embryogenesis in a mouse model. Science 1981; 214:936-938.
5. Committee to Study Fetal Alcohol Syndrome. Fetal Alcohol Syndrome: diagnosis, epidemiology, prevention, and treatment. Washington, DC: National Academy Press, 1996.
6. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther 1998; 285:931-945
7. Law KL, Stroud LR, LaGasse LL, Niaura R, Liu J, Lester BM. Smoking during pregnancy and newborn neurobehavior. Pediatrics 2003; 111:1318-1323
8. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 1989; 84:924-936
9. Jaddoe V, Troe E, Hofman A, Mackenbach J, Moll H, Steegers E, Witteman J. Active and passive maternal smoking during pregnancy and the risks of low birthweight and preterm birth: the Generation R Study. Paediatr Perinat Epidemiol 2008; 22:162-171
10. American Academy of Pediatrics Committee on Substance Abuse. Tobacco's toll: implications for the pediatrician. Pediatrics 2001; 107:794-798
11. Fricker HS, Segal S. Narcotic addiction, pregnancy, and the newborn. Am J Dis Child 1978; 132:360-366
12. Zelson C, Rubio E,Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics 1971; 48:178-189
13. Kaltenbach K. Effects of in-utero opiate exposure: new paradigms for old questions. Drug Alcohol Depend 1994; 36:83-87
14. Kandall SR,Albin S, Lowinson J, Berle B, Eidelman AL, Gartner LM. Differential effects of maternal heroin and methadone use on birth weight. Pediatrics 1976; 58: 681-685
15. Center for Substance Abuse Treatment Consensus Panel. Pregnant, substance-using women [DHHS Publication No. (SMA) 02-3677]. Treatment Improvement Protocol (TIP) Series #2. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993.
16. Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100:1244-1249
17. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189(2):312-317
18. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70:S87-S101.
19. Doberczak TM, Shanzer S, Cutler R, Senie RT, Loucopoulos JA, Kandall SR. One-year follow-up of infants with abstinence-associated seizures. Arch Neurol 1988; 45:649-653
20. Lester BM, Tronick EZ, LaGasse L, Seifer R, Bauer CR, Shankaran S,BadaHS, Wright LL, SmeriglioVL, Lu J, Finnegan LP, Maza PL. The maternal lifestyle study: effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics 2002; 110:1182-1192
21. Das A, Poole WK, Bada HS. A repeated measures approach for simultaneous modeling of multiple neurobehavioral outcomes in newborns exposed to cocaine in utero. Am J Epidemiol 2004; 159:891-899
22. Kandall SR. Treatment strategies for drug-exposed neonates. Clin Perinatol 1999; 26:231-243
23. The American Academy of Pediatrics Task Force on Sudden Infant Death Syndrome. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics 2005; 116:1245-1255
24. Lipsitz PJ. Proposed narcotic withdrawal score for use with newborn-infants: pragmatic evaluation of its efficacy. Clin Pediatr 1975; 14:592-594
25. Finnegan LP, Kaltenbach K. The assessment and management of neonatal abstinence syndrome. In: Hoekelman N, eds. Primary pediatric care. St. Louis, MO: C.V. Mosby Company, 1992:1367-1378
26. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101:1079-1088
27. CoyleMG, Ferguson A, LaGasse L, OhW, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002; 140:561-564
28. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008; 84:29-35.
29. Ornoy A, Segal J, Bar-Hamburger R, Greenbaum C. Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol 2001; 43: 668-675
30. Ornoy A, Michailevskaya V, Lukashov I, BarHamburger R, Harel S. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl 1996; 20:385-396
31. Behnke M, Eyler FD, Garvan CW, Wobie K. The search for congenital malformations in newborns with fetal cocaine exposure. Pediatrics 2001; 107:E74.
32. Bauer CR, Langer JC, Shankaran S, BadaHS, Lester B, Wright LL, Krause-Steinrauf H, Smeriglio VL, Finnegan LP,Maza PL,Verter J. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr AdolescMed 2005; 159:824-834
33. Behnke M, Davis EF, Conlon M, Wobie K, Stewart WN, Cumming W. Incidence and description of structural brain abnormalities in newborns exposed to cocaine. J Pediatr 1998; 132:291-294
34. Bandstra ES, Morrow CE, Anthony JC, Churchill SS, Chitwood DD, Steele BM, Ofir AY, Xue L. Intrauterine growth of full-term infants: impact of prenatal cocaine exposure. Pediatrics 2001; 108:1309-1319 (Pubitemid 33121473)
35. Frank DA, Bauchner H, Parker S, Huber AM, Kyei- Aboagye K, Cabral H, Zuckerman BS. Neonatal body proportionality and body composition after in utero exposure to cocaine and marijuana. J Pediatr 1990; 117:622-626
36. Church MW, Crossland WJ, Holmes PA, Overbeck GW, Tilak JP. Effects of prenatal cocaine on hearing, vision, growth, and behavior. Ann N Y Acad Sci 1998; 846:12-28.
37. Eyler FD, Behnke M, Conlon M,Woods NS,Wobie K. Birth outcome from a prospective, matched study of prenatal crack/cocaine use: I. Interactive and dose effects on health and growth. Pediatrics 1998; 101:229-237 (Pubitemid 28076655)
38. Bateman DA, Chiriboga CA. Dose-response effect of cocaine on newborn head circumference. Pediatrics 2000; 106:e33.
39. Nordstrom-Klee B, Delaney-Black V, Covington C, Ager J, Sokol R. Growth from birth onwards of children prenatally exposed to drugs: a literature review. Neurotoxicol Teratol 2002; 24:481-488 (Pubitemid 34808719)
40. Frank DA, AugustynM, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA 2001; 285:1613-1625
41. Shankaran S, Lester B, Das A, Bauer CR, Bada H, LaGasse L, Higgins R. Impact of maternal substance use during pregnancy on childhood outcome. Semin Fetal Neonatal Med 2007; 12:143-150
42. Covington CY, Nordstrom-Klee B, Ager J, Sokol R, Delaney-Black V. Birth to age 7 growth of children prenatally exposed to drugs: a prospective cohort study. Neurotoxicol Teratol 2002; 24:489-496 (Pubitemid 34804600)
43. Richardson GA, Goldschmidt L, Larkby C. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. Pediatrics 2007; 120:1017-1027
44. Eyler FD, Behnke M. Early development of infants exposed to drugs prenatally. Clin Perinatol 1999; 26:107-150
45. Singer LT, Arendt R, Minnes S, Farkas K, Salvator A. Neurobehavioral outcomes of cocaine-exposed infants. Neurotoxicol Teratol 2000; 22:653-666
46. Morrow CE, Bandstra ES, Anthony JC, Ofir AY, Xue L, Reyes M. Influence of prenatal cocaine exposure on full-term infant neurobehavioral functioning. Neurotoxicol Teratol 2001; 23:533-544 (Pubitemid 34132928)
47. BehnkeM, Eyler FD, Garvan CW,Wobie K, HouW. Cocaine exposure and developmental outcome from birth to 6 months. Neurotoxicol Teratol 2002; 24:283-295
48. Neuspiel DR, Hamel SC, Hochberg E, Greene J, Campbell D. Maternal cocaine use and infant behavior. Neurotoxicol Teratol 1991; 13:229-233
49. Myers BJ, Dawson KS, Britt GC, Lodder DE, Meloy LD, Saunders MK, Meadows SL, Elswick RK. Prenatal cocaine exposure and infant performance on the Brazelton Neonatal Behavioral Assessment Scale. Subst Use Misuse 2003; 38:2065-2096
50. Coles CD, Platzman KA, Smith IE, JamesME, Falek A. Effects of cocaine and alcohol use in pregnancy on neonatal growth and neurobehavioral status. Neurotoxicol Teratol 1992; 14:23-33.
51. Tronick EZ, Frank DA, Cabral H, Mirochnick M, Zuckerman BS. Late dose-response effects of prenatal cocaine exposure on newborn neurobehavioral performance. Pediatrics 1996; 98:76-83.
52. Bendersky M, Lewis M. Arousal modulation in cocaine-exposed infants. Dev Psychol 1998; 34:555-564
53. Schuetze P, Eiden RD. The association between maternal cocaine use during pregnancy and physiological regulation in 4-to 8-week-old infants: an examination of possible mediators and moderators. J Pediatr Psychol 2006; 31:15-26.
54. Corwin MJ, Lester BM, Sepkoski C, McLaughlin S, Kayne H, Golub HL. Effects of in utero cocaine exposure on newborn acoustical cry characteristics. Pediatrics 1992; 89:1199-1203
55. Rotta NT, Cunha GB. [Prenatal exposure to cocaine: review of the neurobehavioral effects]. J Pediatr (Rio J) 2000; 76:179-184
56. Mehta SK, Super DM, Connuck D, Kirchner HL, Salvator A, Singer L, Fradley LG, Kaufman ES.Autonomic alterations in cocaine-exposed infants. Am Heart J 2002; 144:1109-1115
57. Lester BM, LaGasse L, Seifer R, Tronick EZ, Bauer CR, Shankaran S, Bada HS, Wright LW, Smeriglio VL, Liu J, Finnegan LP, Maza PL. The Maternal Lifestyle Study (MLS): effects of prenatal cocaine and/or opiate exposure on auditory brain response at one month. J Pediatr 2003; 142:279-285
58. Tan-Laxa MA, Sison-Switala C, Rintelman W, Ostrea EM. Abnormal auditory brainstem response among infants with prenatal cocaine exposure. Pediatrics 2004; 113:357-360
59. Lester BM, LaGasse LL, Freier K, Brunner SM. Studies of cocaine-exposed human infants. NIDA Res Monogr 1996; 164:175-210.
60. Singer LT, Arendt R, Minnes S, Farkas K, Salvator A, Kirchner HL, Kliegman R. Cognitive and motor outcomes of cocaine-exposed infants. JAMA2002; 287:1952- 1960.
61. LewisMW, Misra S, Johnson HL, Rosen TS. Neurological and developmental outcomes of prenatally cocaineexposed offspring from 12 to 36 months. Am J Drug Alcohol Abuse 2004; 30:299-320.
62. Singer LT, Hawkins S,Huang J, DavillierM,Baley J. Developmental outcomes and environmental correlates of very low birthweight, cocaine-exposed infants. Early Hum Dev 2001; 64:91-103.
63. Mayes LC, Cicchetti D, Acharyya S, Zhang H. Developmental trajectories of cocaine-and-other-drugexposed and non-cocaine-exposed children. J Dev Behav Pediatr 2003; 24:323-335
64. Frank DA, Jacobs RR, Beeghly M, Augustyn M, Bellinger D, Cabral H, Heeren T. Level of prenatal cocaine exposure and scores on the Bayley Scales of Infant Development: modifying effects of caregiver, early intervention, and birth weight. Pediatrics 2002; 110:1143-1152
65. Brown JV, Bakeman R, Coles CD, Platzman KA, Lynch ME. Prenatal cocaine exposure: a comparison of 2- year-old children in parental and nonparental care. Child Dev 2004; 75:1282-1295
66. Richardson GA, Goldschmidt L, Willford J. The effects of prenatal cocaine use on infant development. Neurotoxicol Teratol 2008; 30:96-106.
67. Messinger DS, Bauer CR, Das A, Seifer R, Lester BM, LaGasse LL, Wright LL, Shankaran S, Bada HS, Smeriglio VL, Langer JC, Beeghly M, Poole WK. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004; 113: 1677-1685
68. Miller-Loncar C, Lester BM, Seifer R, LaGasse LL, Bauer CR, Shankaran S, Bada HS, Wright LL, Smeriglio VL, Bigsby R, Liu J. Predictors of motor development in children prenatally exposed to cocaine. Neurotoxicol Teratol 2005; 27:213-220
69. Morrow CE, Bandstra ES, Anthony JC, Ofir AY, Xue LH, ReyesMB. Influence of prenatal cocaine exposure on early language development: longitudinal findings from four months to three years of age. J Dev Behav Pediatr 2003; 24:39-50.
70. Morrow CE, Vogel AL, Anthony JC, Ofir AY, Dausa AT, Bandstra ES. Expressive and receptive language functioning in preschool children with prenatal cocaine exposure. J Pediatr Psychol 2004; 29:543-554
71. Singer LT, Arendt R, Minnes S, Salvator A, Siegel AC, Lewis BA. Developing language skills of cocaine-exposed infants. Pediatrics 2001; 107:1057-1064
72. Johnson JM, Seikel JA, Madison CL, Foose SM, Rinard KD. Standardized test performance of children with a history of prenatal exposure to multiple drugs/cocaine. J Commun Disord 1997; 30:45-72.
73. Bland-Stewart LM, Seymour HN, BeeghlyM, Frank DA. Semantic development of African-American children prenatally exposed to cocaine. Semin Speech Lang 1998; 19:167-186
74. Malakoff ME, Mayes LC, Schottenfeld R, Howell S. Language production in 24-month-old inner-city children of cocaine-and-other-drug-using mothers. J Appl Dev Psychol 1999; 20:159-180
75. Mentis M, Lundgren K. Effects of prenatal exposure to cocaine and associated risk factors on language development. J Speech Hear Res 1995; 38:1303-1318
76. Bandstra ES, MorrowCE,VogelAL, Accornero VH, Ofir AY, Anthony JC. Language development in children exposed to cocaine in utero: a longitudinal perspective. Ital J Pediatr 2003; 29:31-38
77. Vorhees CV, Butcher RE. Behavioral teratology. In: Snell K, ed. Developmental toxicology. New York: Praeger Press, 1982:249-298
78. Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. Ann N Y Acad Sci 1989; 562:31-41.
79. Fried PA. Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry 2002; 43:81-102.
80. Mayes LC. A behavioral teratogenic model of the impact of prenatal cocaine exposure on arousal regulatory systems. Neurotoxicol Teratol 2002; 24:385-395
81. Mayes LC, Grillon C, Granger R, Schottenfeld RS. Regulation of arousal and attention in preschool children exposed to cocaine prenatally. Ann N Y Acad Sci 1998; 846:126-143
82. LaGasse LL, Messinger D, Lester BM, Seifer R, Tronick EZ, Bauer CR, Shankaran S, Bada HS, Wright LL, Smeriglio VL, Finnegan LP, Maza PL, Liu J. Prenatal drug exposure and maternal and infant feeding behaviour. Arch Dis Child 2003; 88:F391-9.
83. Johnson MO. Mother-infant interaction and maternal substance use/abuse: an integrative review of research literature in the 1990s. Online J Knowl Synth Nurs 2001; 8.
84. Mayes LC, Feldman R, Granger RH, Haynes OM, Bornstein MH, Schottenfeld R. The effects of polydrug use with and without cocaine on mother-infant interaction at 3 and 6 months. Infant Behav Dev 1997; 20:489-502.
85. Freier K. In utero drug exposure and maternal-infant interaction: the complexities of the dyad and their environment. Infant Ment Health J 1994; 15:176-188
86. Bandstra ES, Morrow CE, Anthony JC, Accornero VH, Fried PA. Longitudinal investigation of task persistence and sustained attention in children with prenatal cocaine exposure. Neurotoxicol Teratol 2001; 23:545-559
87. Accornero VH, Amado AJ, Morrow CE, Xue LH, Anthony JC, Bandstra ES. Impact of prenatal cocaine exposure on attention and response inhibition as assessed by continuous performance tests. J Dev Behav Pediatr 2007; 28:195-205.
88. Eiden RD, Stevens A, Schuetze P, Dombkowski LE. A conceptual model for maternal behavior among polydrug cocaine-using mothers: the role of postnatal cocaine use and maternal depression. Psychol Addict Behav 2006; 20:1-10.
89. Johnson AL, Bandstra ES, Morrow CE, Accornero VH, Xue L, Anthony JC. Maternal cocaine use: estimated effects on mother-child play interactions in the preschool period. J Dev Behav Pediatr 2002; 23:191-202.
90. Espinosa M, Beckwith L, Howard J, Tyler R, Swanson K. Maternal psychopathology and attachment in toddlers of heavy cocaine-using mothers. Inf Men Health J 2001; 22:316-333
91. Lester BM, LaGasse LL, Seifer R. Cocaine exposure and children: the meaning of subtle effects. Science 1998; 282:633-634
92. Finnegan LP, Hagan T, Kaltenbach K. Opiod dependence: scientific foundations for clinical practice, pregnancy and substance abuse: perspectives and directions. Proceedings of the New York Academy of Medicine 1991; 67:223-229